Wednesday, October 01, 2025 11:31:47 PM
RIP_GOP,
Yep, NWBO is the king maker for combos and Direct will be the King. In the mean time, combos will be the lifesaver for some companies. We have discussed the unwanted possibility by big pharma of a bidding war for rights to outright ownership of NWBO on this board because that would end up being devastating to the loosers. So it seems NWBO basically is proposing dividing up the indications L is used in based on its patent protection for combos where that patent protection has been granted. As I recall, the US has not granted full patent protection for combos yet but others have. So who here thinks that might have something to do with big pharma influence?; ).
Getting approval outside of the United States first allows combo usage to be controlled in countries where there is combo patent protection and what company is going to stop selling their product to folks who have access to both their product and murcidencel with the risk that other products could take their place where the combo is governed by patent protection and NWBO has the upper hand in negotiating combo license fees?; ). Much better to get that worked out early or folks will go to where they can get access to what they want for as cheap as possible and the least amount of red tape. Best wishes.
Yep, NWBO is the king maker for combos and Direct will be the King. In the mean time, combos will be the lifesaver for some companies. We have discussed the unwanted possibility by big pharma of a bidding war for rights to outright ownership of NWBO on this board because that would end up being devastating to the loosers. So it seems NWBO basically is proposing dividing up the indications L is used in based on its patent protection for combos where that patent protection has been granted. As I recall, the US has not granted full patent protection for combos yet but others have. So who here thinks that might have something to do with big pharma influence?; ).
Getting approval outside of the United States first allows combo usage to be controlled in countries where there is combo patent protection and what company is going to stop selling their product to folks who have access to both their product and murcidencel with the risk that other products could take their place where the combo is governed by patent protection and NWBO has the upper hand in negotiating combo license fees?; ). Much better to get that worked out early or folks will go to where they can get access to what they want for as cheap as possible and the least amount of red tape. Best wishes.
Recent NWBO News
- How Advanced Drug Delivery Could Improve Existing Cancer Treatments • GlobeNewswire Inc. • 06/01/2026 12:30:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
